SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis

Huang, Run; Li, Xin; Ye, Yu; Ma, Lisi; Liu, Sixuan; Zong, Xiangyun; Zheng, Qi

doi:10.18632/oncotarget.21583

Cited by 24 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Chen et al revealed that SETD7 overexpression induced HCC cell proliferation, whereas SETD7 knockdown suppressed HCC cell proliferation [31]. Huang et al demonstrated that SETD7 induced breast cancer cell proliferation and suppressed cell apoptosis, which suggested that SETD7 expression level can predict the prognosis of breast cancer [32]. Here, we found that overexpression of SETD7 promoted PTC cell proliferation and inhibited apoptosis, whereas the downregulation of SETD7 had opposite effects on PTC cells.…”

Section: Discussionsupporting

confidence: 53%

MiR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7

Zhao¹,

Wang²,

Shang³

et al. 2020

aoms

View full text Add to dashboard Cite

Introduction: This study aimed to explore the effects of miR-345-5p on papillary thyroid carcinoma (PTC) and uncover the possible mechanisms. Material and methods: MiR-345-5p and SETD7 mRNA levels were analyzed by quantitative real-time PCR and SETD7 protein level was measured by Western blot. The viability, colony formation ability and apoptosis of PTC cells were measured with CCK-8, soft agar colony formation and flow cytometry assay, respectively. Luciferase reporter assay was used to identify miR-345-5p's target. Results: Compared to neighboring normal tissues, there was lower miR-345-5p expression and higher SETD7 expression in PTC tissues. Moreover, Spearman's correlation analysis indicated that there was a negative correlation between miR-345-5p and SETD7 expression in PTC tissues. MiR-345-5p mimics inhibited the viability and colony formation of TPC1 and B-CPAP cells and promoted apoptosis, whereas anti-miR-345-5p promoted PTC cell proliferation and inhibited apoptosis. SETD7 was confirmed to be a direct target of miR-345-5p through target scan analysis and luciferase reporter assay. Additionally, overexpression of SETD7 promoted the viability and colony formation of TPC1 and B-CPAP cells and inhibited apoptosis, whereas downregulation of SETD7 by shRNAs had opposite effects on PTC cells. Furthermore, overexpression of SETD7 attenuated the miR-345-5p induced anti-tumor effects on PTC cells. Conclusions: MiR-345-5p exhibited suppressive effects on PTC via targeting SETD7.

show abstract

Section: Discussionsupporting

confidence: 53%

MiR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7

Zhao¹,

Wang²,

Shang³

et al. 2020

aoms

View full text Add to dashboard Cite

show abstract

“…SETD7 (also known as SET7/9) is a 41 kDa lysine-specific SET-domain methyltransferase, which is the only lysine methyltransferases (KMT)7 family member due to its unique enzymatic activity and protein domain architecture [ 23 ]. Recent investigations indicated that SETD7 is potentially a biomarker for hepatocellular cancer [ 24 ] and breast cancer [ 25 , 26 ], although the role of SETD7 in breast cancer is controversial [ 25 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients

et al. 2018

View full text Add to dashboard Cite

BackgroundThere is an urgent need for the identification of new, clinically useful biomarkers of CRC to enhance diagnostic and prognostic capabilities.MethodsWe performed proteomic profiling on serum samples from paired pre- and post-operative CRC patients, colorectal polyps patients and healthy controls using an approach combining magnetic bead-based weak cation exchange and matrix-assisted laser desorption ionization-time of flight mass spectrometry. We next performed liquid chromatography-electrospray ionization-tandem mass spectrometry to identify the proteins and selected potential biomarker based on bioinformatics analysis of the TCGA and GEO dataset. We examined SETD7 expression in serum and tissue samples by ELISA and immunohistochemistry respectively and explored the biological function of SETD7 in vitro.Findings85 differentially expressed peptides were identified. Five peptides showing the most significant changes in abundance across paired pre- and post-operation CRC patients, colorectal polyps patients and healthy controls were identified as peptide regions of FGA, MUC5AC and SETD7. Bioinformatics analysis suggested that the up-regulation of SETD7 in CRC is relatively specific. Validation studies showed that SETD7 expression increased from healthy controls to those with colorectal polyps and finally CRC patients, and decreased after surgery. The sensitivity and specificity of SETD7 were 92.17% and 81.08%, with a high diagnostic value (AUC = 0.9477). In addition, SETD7 expression was significantly correlated with tumor stage and microsatellite instability. Knockdown of SETD7 inhibited cancer cell proliferation, induced G1/S cell cycle arrest and increased apoptosis.InterpretationOur data indicate that SETD7 could serve as a potential diagnostic and prognostic biomarker for CRC.

show abstract

“…SETD7 is the only lysine methyltransferases seven family members which can methylate transcription factors [31]. SETD7 could be used as a prognostic indicator for breast cancer, downregulation of it suppressed expression of antioxidant enzymes and destabilized the redox status [32]. SETD7 and ISL1 may combine to form a complex on the ZEB1 promoter to promote tumorigenesis in GC cells [33].…”

Section: Discussionmentioning

confidence: 99%

Systematic Construction and Validation of an RNA Binding Proteins-Based Signature for Prognostic Prediction in Gastric Cancer

Zhang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is one of the most common cancers with high incidence and mortality worldwide. Recently, RNA-binding proteins (RBPs) have drawn more and more attention for its role in cancer pathophysiology. In this study, we aim to explore the function and clinical implication of RBPs in GC. Methods: RNA sequencing data along with the corresponding clinical information of GC patients were downloaded from The Cancer Genome Atlas (TCGA) database. Differentially expressed RNA-binding proteins (DERBPs) between tumor and normal tissues were identified by ‘limma’ package. Functional enrichment analysis and the protein-protein interaction (PPI) network were harnessed to explore the function and interaction of DERBPs. Next, Univariate and multiple Cox regression were applied to screen prognosis-related hub RBPs and to construct a signature for BC. Meanwhile, a nomogram was built based on the same RBPs. Results: A total of 296 DERBPs were found, and most of them mainly related to post-transcriptional regulation of RNA and ribonucleoprotein. A PPI network of DERBPs was constructed, consisting of 262 nodes and 2567 edges. A prognostic signature was built depended on seven prognosis-related hub RBPs that could divide GC patients into high- and low-risk groups. Survival analysis showed that the high-risk group had a worse prognosis compared to the low-risk group and the time-dependent receiver operating characteristic (ROC) curves suggested that the signature existed moderate predictive capacities of survival for GC patients. Similar results were obtained from another independent set GSE84437, confirming the robustness of signature. Calibration plots reported good consistency between overall survival (OS) prediction by nomogram and actual observation. Conclusion: The findings of this study would provide evidence of the effect of RBPs on GC as well as offering novel potential biomarkers in prognosis prediction and clinical decision for GC patients.

show abstract

SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis

Cited by 24 publications

References 34 publications

MiR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7

MiR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7

Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients

Systematic Construction and Validation of an RNA Binding Proteins-Based Signature for Prognostic Prediction in Gastric Cancer

Contact Info

Product

Resources

About